Navigation Links
Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
Date:8/29/2007

SOUTH SAN FRANCISCO, Calif., Aug. 29 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold a webcast briefing for analysts and investors in conjunction with the International Association for the Study of Lung Cancer's (IASLC) 12th World Conference on Lung Cancer. The webcast will be held on Wednesday, September 5, 2007, at 5:00 a.m. PDT/8:00 a.m. EDT. During the webcast, Exelixis management will discuss data from a Phase 2 trial of XL647 in non-small cell lung cancer patients presented at the Conference.

The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archive of this webcast will be available until 8:59 p.m. PDT/11:59 p.m. EDT on October 5, 2007. Access numbers for this replay are 888-286-8010 (domestic) and 617-801-6888 (international). The replay passcode is 18807116.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 Since ... matured into an essential life science tool for conducting ... applications. BCC Research reveals in its new report that ... growth phase, one powered by a range of new ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
Breaking Medicine Technology:
(Date:5/26/2016)... NJ (PRWEB) , ... May 26, 2016 , ... ... recognized as an NJ Top Doc! Along with his wonderful accolades and stellar ... in podiatry. Congratulations, Dr. Batelli! , Dr. Eugene Batelli is a highly ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, ... the first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led ... professional through the 8 hour interactive course to qualify participants as certified PowerWave ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... ... May 26, 2016 , ... OncLive® , a ... Cancer Institute-designated University of Virginia (UVA) Cancer Center to its quickly ... and marketing teams will publicize and promote public awareness of UVA Cancer Center’s ...
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National Eye ... and international water advocate, was honored by Ashram, Inc. as the world’s foremost water ... knelt on the banks of the Nile to fill their red clay pots with ...
Breaking Medicine News(10 mins):